NO980221L - Fremgangsmåte for behandling av tykktarmsadenomer - Google Patents

Fremgangsmåte for behandling av tykktarmsadenomer

Info

Publication number
NO980221L
NO980221L NO980221A NO980221A NO980221L NO 980221 L NO980221 L NO 980221L NO 980221 A NO980221 A NO 980221A NO 980221 A NO980221 A NO 980221A NO 980221 L NO980221 L NO 980221L
Authority
NO
Norway
Prior art keywords
procedure
treatment
patient
pghs
colon adenomas
Prior art date
Application number
NO980221A
Other languages
English (en)
Other versions
NO980221D0 (no
Inventor
Stacia Kargman
Thomas J Simon
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603470.7A external-priority patent/GB9603470D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of NO980221D0 publication Critical patent/NO980221D0/no
Publication of NO980221L publication Critical patent/NO980221L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lasers (AREA)
  • Harvester Elements (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Soil Working Implements (AREA)

Abstract

Fremgangsmåte for å forsinke eller forhindre transformering av et tykktarmsadenom til et tykktarmsadenomkarsinom, omfattende administrering av en ikke-toksisk terapeutisk effektiv mengde av NSAID som effektivt inhiberer PGHS-2 i ovennevnte adenom, til en pasient med FAP eller en pasient med en eller flere av de ovennevnte adenomer. Den foretrukne fremgangsmåte omfatter administrering av et spesifikt PGHS-2-inhiberende middel.
NO980221A 1995-07-19 1998-01-16 Fremgangsmåte for behandling av tykktarmsadenomer NO980221L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US124095P 1995-07-19 1995-07-19
GBGB9603470.7A GB9603470D0 (en) 1996-02-19 1996-02-19 Method of treating colonic adenomas
PCT/US1996/011761 WO1997003667A1 (en) 1995-07-19 1996-07-15 Method of treating colonic adenomas

Publications (2)

Publication Number Publication Date
NO980221D0 NO980221D0 (no) 1998-01-16
NO980221L true NO980221L (no) 1998-03-18

Family

ID=26308761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980221A NO980221L (no) 1995-07-19 1998-01-16 Fremgangsmåte for behandling av tykktarmsadenomer

Country Status (17)

Country Link
EP (1) EP0839034B1 (no)
KR (1) KR100454624B1 (no)
CN (1) CN1196679A (no)
AT (1) ATE268176T1 (no)
AU (1) AU706089B2 (no)
CA (1) CA2227238C (no)
CZ (1) CZ294516B6 (no)
DE (1) DE69632632T2 (no)
EA (1) EA005073B1 (no)
ES (1) ES2220983T3 (no)
HU (1) HU225506B1 (no)
IL (1) IL122960A (no)
MX (1) MX9800568A (no)
NO (1) NO980221L (no)
NZ (1) NZ312997A (no)
SK (1) SK5298A3 (no)
WO (1) WO1997003667A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
AU750125B2 (en) * 1997-08-27 2002-07-11 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
ES2255287T3 (es) * 1998-07-09 2006-06-16 Cephalon, Inc. Composiciones para el tratamiento de la leucemia linfocitica cronica.
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
CN1659131A (zh) 2002-04-08 2005-08-24 葛兰素集团有限公司 2－((2－烷氧基)－苯基)－环戊－1－烯基)芳香碳－以及杂环羧酸及其衍生物
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
TW200735866A (en) * 2005-11-18 2007-10-01 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
AU2008206045A1 (en) * 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物
DE69529690T2 (de) * 1994-12-21 2003-11-13 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren

Also Published As

Publication number Publication date
EA199800139A1 (ru) 1998-08-27
ES2220983T3 (es) 2004-12-16
EP0839034A1 (en) 1998-05-06
CZ15698A3 (cs) 1998-09-16
SK5298A3 (en) 1998-12-02
WO1997003667A1 (en) 1997-02-06
HU225506B1 (en) 2007-01-29
IL122960A (en) 2006-07-05
CZ294516B6 (cs) 2005-01-12
DE69632632T2 (de) 2005-05-25
EP0839034A4 (en) 2002-06-19
CA2227238A1 (en) 1997-02-06
AU706089B2 (en) 1999-06-10
ATE268176T1 (de) 2004-06-15
EP0839034B1 (en) 2004-06-02
DE69632632D1 (de) 2004-07-08
NO980221D0 (no) 1998-01-16
IL122960A0 (en) 1998-08-16
AU6496096A (en) 1997-02-18
KR100454624B1 (ko) 2004-12-31
EA005073B1 (ru) 2004-10-28
HUP9901711A2 (hu) 1999-09-28
CA2227238C (en) 2003-10-28
MX9800568A (es) 1998-04-30
CN1196679A (zh) 1998-10-21
KR19990029066A (ko) 1999-04-15
HUP9901711A3 (en) 2001-02-28
NZ312997A (en) 2000-07-28

Similar Documents

Publication Publication Date Title
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU5624699A (en) Use of 5ht-6 antagonists
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
CA2304657A1 (en) Treatment of conduct disorder
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
EE200000685A (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
EP0756869A3 (en) Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
NO20003813L (no) FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO982562L (no) Sammensetning for behandling av smerte
DK0841937T4 (da) Anvendelse af betaglycan til reduktion af ardannelse
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DK0968174T3 (da) Optisk aktiv 2-aminotetralin, fremgangsmåde til dets fremstilling og farmaceutiske præparater indeholdende selv samme, effektiv til forebyggelse og behandling af septisk chok
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application